SIRTCI, NCT04659382: Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 52 | Europe | Atezolizumab, Therasphere, XELOX, Bevacizumab | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy | 10/24 | 10/24 | | |
